AXSOME THERAPEUTICS, INC. Net Change in Cash
AXSOME THERAPEUTICS, INC. (AXSM) reported Net Change in Cash of -$3.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$17.83M.
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$14.44M.
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$54.75M, a 219.88% decline year-over-year.
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $45.67M.
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $7.58M.
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$70.84M, a 138.22% decline from fiscal 2023.
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $185.35M, a 62.06% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $114.37M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.08M 10-Q · filed 2026-08-10 | |||||||
| 2026-03-31 | -$17.83M 10-Q · filed 2026-05-04 | |||||||
| 2025-12-31 | $7.58M 10-K · filed 2026-02-23 | |||||||
| 2025-09-30 | $9.92M 10-Q · filed 2025-11-03 | |||||||
| 2025-06-30 | -$12.34M 10-Q · filed 2026-08-10 | |||||||
| 2025-03-31 | -$14.44M 10-Q · filed 2026-05-04 | |||||||
| 2024-12-31 | -$70.84M 10-K · filed 2026-02-23 | |||||||
| 2024-09-30 | -$58.85M 10-Q · filed 2025-11-03 | |||||||
| 2024-06-30 | -$70.54M 10-Q · filed 2025-08-04 | |||||||
| 2024-03-31 | -$54.75M 10-Q · filed 2025-05-05 | |||||||
| 2023-12-31 | $185.35M 10-K · filed 2026-02-23 | |||||||
| 2023-09-30 | $215.72M 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | $236.27M 10-Q · filed 2024-08-05 | |||||||
| 2023-03-31 | $45.67M 10-Q · filed 2024-05-06 | |||||||
| 2022-12-31 | $114.37M 10-K · filed 2025-02-18 | $114.37M 10-K · filed 2023-02-28 | ||||||
| 2022-09-30 | $141.05M 10-Q · filed 2023-11-06 | $141.05M 10-Q · filed 2022-11-07 | ||||||
| 2022-06-30 | -$13.08M 10-Q · filed 2023-08-07 | -$13.08M 10-Q · filed 2022-08-09 | ||||||
| 2022-03-31 | -$1.76M 10-Q · filed 2023-05-09 | -$1.77M 10-Q · filed 2022-05-02 | ||||||
| 2021-12-31 | -$97.40M 10-K · filed 2024-02-23 | -$97.40M 10-K · filed 2022-03-01 | ||||||
| 2021-09-30 | -$69.25M 10-Q · filed 2022-11-07 | |||||||
| 2021-06-30 | -$42.66M 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | -$19.22M 10-Q · filed 2022-05-02 | |||||||
| 2020-12-31 | -$36.09M 10-K · filed 2023-02-28 | |||||||
| 2020-09-30 | -$17.61M 10-Q · filed 2021-11-08 | |||||||
| 2020-06-30 | -$29.28M 10-Q · filed 2021-08-09 | |||||||
| 2020-03-31 | -$22.65M 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | $206.00M 10-K · filed 2022-03-01 | |||||||
| 2019-09-30 | $29.67M 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | $39.78M 10-Q · filed 2020-08-10 | |||||||
| 2019-03-31 | $28.66M 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | -$20.05M 10-K · filed 2021-03-01 | |||||||
| 2018-09-30 | -$18.80M 10-Q · filed 2019-11-07 | |||||||
| 2018-06-30 | -$13.67M 10-Q · filed 2019-08-08 | |||||||
| 2018-03-31 | -$7.39M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$2.60M 10-K · filed 2020-03-12 | |||||||
| 2017-09-30 | -$4.95M 10-Q · filed 2018-11-09 | |||||||
| 2016-12-31 | -$11.42M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |